CERO Therapeutics Advances with FDA Approval for CER-1236
By ATTN Desk · Editorial oversight: Sean Han
Introduction
CERO Therapeutics Holdings Inc (NASDAQ: CERO) is a clinical-stage biotechnology company headquartered in South San Francisco. The firm develops Chimeric Engulfment Receptor T cells (“CER-T”), an engineered cell therapy platform that incorporates both innate and adaptive immune mechanisms into a single T cell. CERO’s lead candidate, CER-1236, targets acute myeloid leukemia (AML) and is designed to employ phagocytic pathways to clear tumor cells.
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| CERO | NASDAQ | 10.8501 | +57.98 | 3,361,931 |
Corporate Structure and Team
According to LinkedIn, CERO employs between 11 and 50 staff members. The executive leadership includes Chris Ehrlich (Chief Executive Officer) and Robert Sikorski, MD, PhD (Chief Medical Officer), alongside co-founder Daniel Corey, MD. CERO maintains strategic partnerships with academic institutions such as UC Davis and contract manufacturing organizations to support its clinical programs.
Recent Developments
On March 27, 2025, CERO announced that the U.S. Food and Drug Administration (FDA) granted a positive review of its CMC (Chemistry, Manufacturing and Controls) amendment for CER-1236. This milestone cleared the way for first-in-human dosing in the first half of 2025. Concurrently, an abstract on CER-1236 was accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago from May 30 to June 5, 2025.
On May 8, 2025, CERO regained compliance with Nasdaq Listing Rule 5550(b)(1) after executing a private placement of Series D preferred stock, drawing down on an equity line of credit, and closing a public offering in February 2025. This restored the company’s minimum stockholders’ equity to at least $2.5 million.
On June 16, 2025, the company filed a Prospectus Supplement (Form 424B3) for an offering of 2,100,000 shares of common stock, with the last quoted sale price of $7.31 per share as of June 13, 2025. Form 8-K filings on June 13 and June 17, 2025, further disclosed material events and exhibits, although detailed contents require review of the SEC filings themselves.
Financial and Strategic Analysis
CERO’s share price rose on June 17, 2025, reflecting increased trading interest. The company operates with no reported revenue to date and reported a net loss of $14.24 million over the trailing twelve months, with a negative diluted EPS of 493.37. As of the most recent balance sheet, CERO held approximately $5.2 million in cash and generated a levered free cash flow deficit of $11.19 million for the period. The company's status as an “emerging growth company” allows reduced reporting requirements under the JOBS Act.
Capital raising activities—including private placements, an equity line of credit, a public offering, and the June stock offering—are part of CERO’s financial strategy to fund clinical development and maintain Nasdaq compliance. The company’s low beta (0.43) suggests that its stock has exhibited less volatility relative to the broader market over the past five years.
Market Position and Industry Context
CERO operates within the immuno-oncology sector, specifically in the engineered T cell therapy subsegment. Current commercial CAR-T products address certain hematological malignancies, while CERO’s CER-T platform aims to expand application to both blood cancers and solid tumors via phagocytic clearance pathways. The FDA’s Orphan Drug Designation for CER-1236 in AML reflects regulatory support for therapies targeting rare cancers. Presentation at ASCO positions CERO among other biopharma and biotech firms showcasing early-stage data. Partnerships with academic and manufacturing entities are aimed at enhancing its competitiveness in a field shared with companies such as Novartis and Gilead.
tl;dr
- On March 27, 2025, the FDA granted positive CMC review for CER-1236, enabling Phase 1 patient dosing in H1 2025.
- An abstract on CER-1236 was accepted for ASCO 2025 (May 30–June 5 in Chicago).
- On May 8, 2025, CERO regained Nasdaq compliance (Rule 5550(b)(1)) via Series D preferred, equity line drawdown, and public offering.
- On June 16, 2025, CERO filed a Form 424B3 for 2.1 million shares at $7.31 each.
- As of June 17, 2025, the stock traded at $10.8501 (+57.98%) on volume of 3,361,931.
- The company continues to fund clinical development through capital raises, with first-in-human dosing anticipated in the coming weeks.